BRNS
Barinthus Biotherapeutics plc0.7385
-0.0015-0.2%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
30.15MP/E (TTM)
-Basic EPS (TTM)
-1.88Dividend Yield
0%Recent Filings
8-K
10-Q
Q3 FY2025 results
Barinthus Biotherapeutics posted a Q3 net loss of $14.6 million, up from $8.1 million a year earlier, as license revenue vanished after 2024's $15 million windfall from Vaxzevria sales. Research and development costs dropped 48.4% year-over-year to $5.4 million, reflecting pipeline prioritization toward immunology and inflammation programs like VTP-1000 in celiac disease, while general and administrative expenses fell 61.5% to $5.2 million amid headcount reductions and a $3.0 million foreign exchange gain. An impairment charge of $4.7 million hit intangible assets tied to the announced all-stock merger with Clywedog, expected to close in H1 2026 and blend portfolios in metabolic and autoimmune diseases. Cash and equivalents stood at $74.3 million as of September 30, 2025, funding operations into early 2027, with free cash flow not disclosed in the 10-Q. Yet merger delays could strain liquidity.
8-K
Barinthus Q3 loss, Clywedog merger
Barinthus Biotherapeutics announced Q3 2025 results, posting a $14.6 million net loss amid $5.4 million R&D spend and $4.7 million asset impairment from its Clywedog merger valuation. The all-stock merger, signed September 30, 2025, targets closing H1 2026, blending pipelines in metabolic and autoimmune diseases for four data readouts within 18 months. Cash stands at $75.7 million, funding operations into 2027. Merger risks could delay benefits.
8-K
Barinthus merges with Clywedog
Barinthus Biotherapeutics announced a merger with Clywedog Therapeutics on September 29, 2025, forming a combined entity focused on metabolic and autoimmune therapies. Beacon shareholders receive one Topco share per ordinary share, while Clywedog holders get 4.358932 shares per share, yielding 34% and 66% ownership respectively; a potential $27 million self-tender offer precedes the deal. The transaction, eyed for H1 2026 close, bolsters a pipeline with CLY-101 for diabetes, CLY-201 for T1D inflammation, and VTP-1000 for celiac, targeting four milestones by mid-2026 amid regulatory and approval risks. This merger sharpens focus on disease-modifying assets.
10-Q
Q2 FY2025 results
Barinthus Biotherapeutics posted a Q2 net loss of $21.1 million, up 25% year-over-year from $16.9 million, driven by a $8.0 million foreign exchange hit in general and administrative costs that outpaced a 32% drop in R&D spending to $8.0 million as the company sharpened focus on its celiac program. Operating losses widened to $23.3 million, while diluted EPS slipped to $(0.52) from $(0.43), aligning with 40.3 million weighted shares and no anti-dilution effects. Cash burned $33.0 million in operations for the half-year, leaving $87.8 million on hand—enough to reach early 2027. Strategic cuts trimmed headcount and deprioritized oncology and infectious disease efforts. Pipeline prioritization pays off. Yet regulatory delays in clinical trials loom large.
ABUS
Arbutus Biopharma Corporation
4.59-0.36
BVAXD
BioVaxys Technology Corp.
0.15-0.03
DNTH
Dianthus Therapeutics, Inc.
41.40-0.52
FBRX
Forte Biosciences, Inc.
23.27+1.31
PVCT
Provectus Biopharmaceuticals, I
0.06+0.00
THAR
Tharimmune, Inc.
2.41+0.01
VERA
Vera Therapeutics, Inc.
48.30-0.91
VIR
Vir Biotechnology, Inc.
6.48-0.24
VTYX
Ventyx Biosciences, Inc.
8.21-0.13
VYNE
VYNE Therapeutics Inc.
0.40+0.04